title: The EVOLVE study is negative, so what does this 'bitter pill' of disappointment mean now for renal patients?
abstract: The extremely high morbidity and mortality experienced by subjects with chronic kidney disease (CKD) has often been described and reviewed, but this familiarity should not breed indifference to the huge burden of premature cardiovascular disease – something which becomes more obvious, but increasingly challenging to treat, as GFR declines, or proteinuria increases. The health outcomes for a middle-aged person entering renal replacement therapy are as bad as those seen with a major solid organ malignancy; while there has been modest progress in improving outcomes over the last two decades, the diagnosis of significant or progressive CKD should and thus still does continue to cast a shadow over patients, carers and healthcare professionals alike.
authors.affiliation: Nephrology, Guy's Hospital, King's Health Partners, London, UK.
authors.forename: D
authors.initials: D
authors.lastname: Goldsmith
authors.forename: A
authors.initials: A
authors.lastname: Covic
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D057966:Calcimimetic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D000069449:Cinacalcet; D006801:Humans; D006961:Hyperparathyroidism / Q000188:drug therapy*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009281:Naphthalenes / Q000627:therapeutic use*; D010281:Parathyroid Hormone / Q000378:metabolism; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000628:therapy; D017582:Renal Replacement Therapy; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D057966:Calcimimetic Agents; D009281:Naphthalenes; D010281:Parathyroid Hormone; D000069449:Cinacalcet